Pharmacokinetics of ABT-122, a TNF-α- and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials.
Khatri, Amit
Pharmacokinetics of ABT-122, a TNF-α- and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials. [electronic resource] - Clinical pharmacokinetics 05 2018 - 613-623 p. digital
Publication Type: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1179-1926
10.1007/s40262-017-0580-y doi
Adolescent
Adult
Aged
Antirheumatic Agents--blood
Arthritis, Rheumatoid--metabolism
Double-Blind Method
Female
Healthy Volunteers
Humans
Immunoglobulins--blood
Interleukin-17--antagonists & inhibitors
Male
Middle Aged
Tumor Necrosis Factor-alpha--antagonists & inhibitors
Young Adult
Pharmacokinetics of ABT-122, a TNF-α- and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials. [electronic resource] - Clinical pharmacokinetics 05 2018 - 613-623 p. digital
Publication Type: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1179-1926
10.1007/s40262-017-0580-y doi
Adolescent
Adult
Aged
Antirheumatic Agents--blood
Arthritis, Rheumatoid--metabolism
Double-Blind Method
Female
Healthy Volunteers
Humans
Immunoglobulins--blood
Interleukin-17--antagonists & inhibitors
Male
Middle Aged
Tumor Necrosis Factor-alpha--antagonists & inhibitors
Young Adult